[et_pb_section fb_built=”1″ _builder_version=”4.25.0″ _module_preset=”default” background_image=”https:\/\/xtrategicalpharma.com\/wp-content\/uploads\/2024\/05\/Design-sem-nome-3.png” custom_padding=”121px||121px|||” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.19.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.19.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.19.2″ _module_preset=”default” title_font=”Poppins||||||||” title_text_align=”center” title_text_color=”#FFFFFF” title_font_size=”49px” title_font_size_tablet=”49px” title_font_size_phone=”28px” title_font_size_last_edited=”on|phone” global_colors_info=”{}”]
\n[\/et_pb_post_title][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”40px||0px|||” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” make_equal=”on” _builder_version=”4.19.2″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”50%” width_tablet=”50%” width_phone=”90%” width_last_edited=”on|phone” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title title=”off” meta=”off” _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”||50px|||” global_colors_info=”{}”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.0″ text_font=”Roboto|300|||||||” text_text_color=”#416AA4″ text_font_size=”16px” background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
On April 10, 2024, the proposal for the reform of EU pharmaceutical legislation was approved, for a new European directive and regulation, to promote innovation, guarantee access to medicines and more affordable prices, while supporting research, namely new antibiotics, the competitiveness and attractiveness of the EU pharmaceutical industry, with stricter environmental standards and the strengthening of preparedness and response mechanisms for crisis situations.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
On April 10, 2024, the proposal for the reform of EU pharmaceutical legislation was approved, for a new European directive and regulation, to promote innovation, guarantee access to medicines and more affordable prices, while supporting research, namely new antibiotics, the competitiveness and attractiveness of the EU pharmaceutical industry, with stricter environmental standards and the strengthening […]<\/p>\n","protected":false},"author":1,"featured_media":393388,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\r\n
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!<\/p>\r\n","_et_gb_content_width":"2880","footnotes":""},"categories":[24],"tags":[],"class_list":["post-393598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-en"],"yoast_head":"\n